Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant

Mucosal immunity provides efficient protection against upper-airway infections, limiting viral shedding and transmission. However, currently, no nasal spray COVID-19 vaccines are approved by WHO for global use. Here we develop a two-component intranasal vaccine that combines an adenovirus vector expressing the spike protein of the XBB.1.5 variant (Ad5<sub>XBB.1.5</sub>) with a self-assembled trimeric recombinant protein derived from the receptor binding domain (RBD<sub>XBB.1.5</sub>-HR). This two-component vaccine elicits superior humoral and cellular immunity against XBB.1.5 variants compared with the individual components. It also provides protective immunity against live XBB.1.16 virus challenges in mice, and prevents XBB.1.5 virus transmission in a hamster model. Notably, the activation of the STING signalling pathway in mucosal dendritic cells is essential for the adjuvant effect of the adenovirus vector. We also incorporate another trimeric protein from the BA.5 variant (RBD<sub>BA.5</sub>-HR), creating a three-component vaccine (Ad5<sub>XBB.1.5</sub> + RBD<sub>XBB.1.5</sub>-HR + RBD<sub>BA.5</sub>-HR) that shows enhanced broad-spectrum neutralization. The two-component vaccine demonstrates high tolerability and safety in humans, inducing enhanced mucosal immunity and high levels of neutralizing antibodies in all participants. Our findings underscore this strategy for clinical COVID-19 intranasal vaccine development.

Authors

Institutions

Publication Details

Journal
Nature Biomedical Engineering
Published
2025-09-22
DOI
https://doi.org/10.1038/s41551-025-01517-2
Citations
3
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
4.19
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant

Yuquan Wei, Xiawei Wei, Xiangrong Song, Wenyan Ren et al.
3 citations
Nature Biomedical Engineering
SARS-CoV-2 and COVID-19 Research
4.19
article

Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant

Yuquan Wei, Xiawei Wei, Xiangrong Song, Wenyan Ren, Yanan Zhou, Weiqi Hong, Yuhe Huang, Bai Li, Jiayuan Ai, Xikun Zhou, Jingmei Li, Aqu Alu, Zhenfei Bi, Minyang Fu, Youchun Wang, Danyi Ao, Haiying Que, Jinliang Yang, Xiangyu Pan, Guobo Shen, Ping Cheng, Binhan Wang, Xuejiao Han, Zhen Zeng, Chunjun Ye, Haohao Dong, Mengli Yang, Wei Cheng, Guangwen Lu, Jian Lei, Qiangming Sun, Dandan Peng, Hongbo Hu, Shuaiyao Lu, Wenhai Yu, Weimin Li, H. J. Yang, Li Chen, Wei Wang, Lu Chen, Min Luo, Li Yang, Jiong Li, Shi H, Yun Yang, Jian Liu, Xuemei He, Junbin Wang, Cong Tang, Xiya Huang, Cai He, Ying Hao, Yu Zhang, Lei Hong, Qing Huang
article en
3 citations

Abstract

Mucosal immunity provides efficient protection against upper-airway infections, limiting viral shedding and transmission. However, currently, no nasal spray COVID-19 vaccines are approved by WHO for global use. Here we develop a two-component intranasal vaccine that combines an adenovirus vector expressing the spike protein of the XBB.1.5 variant (Ad5<sub>XBB.1.5</sub>) with a self-assembled trimeric recombinant protein derived from the receptor binding domain (RBD<sub>XBB.1.5</sub>-HR). This two-component vaccine elicits superior humoral and cellular immunity against XBB.1.5 variants compared with the individual components. It also provides protective immunity against live XBB.1.16 virus challenges in mice, and prevents XBB.1.5 virus transmission in a hamster model. Notably, the activation of the STING signalling pathway in mucosal dendritic cells is essential for the adjuvant effect of the adenovirus vector. We also incorporate another trimeric protein from the BA.5 variant (RBD<sub>BA.5</sub>-HR), creating a three-component vaccine (Ad5<sub>XBB.1.5</sub> + RBD<sub>XBB.1.5</sub>-HR + RBD<sub>BA.5</sub>-HR) that shows enhanced broad-spectrum neutralization. The two-component vaccine demonstrates high tolerability and safety in humans, inducing enhanced mucosal immunity and high levels of neutralizing antibodies in all participants. Our findings underscore this strategy for clinical COVID-19 intranasal vaccine development.

Nature Biomedical Engineering
Kunming Institute of Zoology (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Sichuan University (CN), Kunming Medical University (CN), Second Affiliated Hospital of Kunming Medical College (CN), State Key Laboratory of Biotherapy
Openalex Percentile: Top 5%
SARS-CoV-2 and COVID-19 Research
4.19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.